<DOC>
	<DOCNO>NCT01403285</DOCNO>
	<brief_summary>BACKGROUND : Active immunotherapy cancer base premise vaccine raise cytotoxic immune response tumor-associated antigen , thereby destroy malignant cell without harm normal cell . IMA950 therapeutic multi-peptide vaccine contain 11 tumor-associated peptide ( TUMAPs ) find majority glioblastoma , design activate TUMAP-specific T cell . The use 11 TUMAPs increase likelihood multi-clonal , highly specific T-cell response tumor cell lead decreased likelihood immune evasion tumor down-regulation target antigen . PURPOSE : The primary objective study determine safety tolerability IMA950 give cyclophosphamide , granulocyte macrophage-colony stimulating factor ( GM-CSF ) imiquimod patient glioblastoma determine IMA950 show sufficient immunogenicity patient . ELIGIBILITY : Patients histologically proven GBMs complete radiotherapy , stable disease follow least 4 cycle adjuvant temozolomide .</brief_summary>
	<brief_title>Peptide-based Glioma Vaccine IMA950 Patients With Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven glioblastoma Stable disease follow ≥ 4 cycle adjuvant temozolomide No progression recurrence disease PATIENT CHARACTERISTICS : HLAA*02 positive ≥ 18 year old Life expectancy &gt; 8 week Karnofsky performance status ≥ 60 WBC &gt; 3,500/µL ALC &gt; 350/mm3 ANC &gt; 1,500/mm3 Platelet count &gt; 100,000/mm3 Hemoglobin &gt; 10gm/dL AST , ALT alkaline phosphatase &lt; 2.5 time upper limit normal ( ULN ) Bilirubin &lt; 1.5 time ULN Creatinine &lt; 1.5 mg/dL and/or creatinine clearance &gt; 60cc/min Serum potassium , magnesium calcium within normal level ( supplementation allow ) Not pregnant nursing Negative pregnancy test Practice birth control 2 month treatment IMA950 ( gender ) Women childbearing age must agree use adequate contraceptive method No significant active hepatic , renal , infectious psychiatric disease No HIV , active hepatitis infection , active severe infectious disease No history autoimmune disease immunosuppression No clinically significant cardiovascular event within 3 month study entry increase risk ventricular arrhythmia No malignancy glioblastoma require treatment last 12 month PRIOR and/or CONCURRENT THERAPY : See Disease Characteristics Completed radiotherapy least 4 cycle adjuvant temozolomide Not receive steroid OR stable dose steroid ≥ 5 day prior registration No prior immunotherapy glioblastoma No major surgery within 4 week prior treatment start At least 4 week cytotoxic therapy ( incl . temozolomide ) At least 2 week noncytotoxic therapy ( e.g . interferon , tamoxifen ) At least 3 week bevacizumab No current treatment imiquimod ; prior use imiquimod allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Glioblastoma</keyword>
	<keyword>stable disease</keyword>
</DOC>